FDA-Approved Ovarian Cancer Treatments
FDA-APPROVED OVARIAN CANCER TREATMENTS
Generic Brand Strength Form Usual Dose
Alkylating agent
altretamine Hexalen 50mg caps 260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle
carboplatin 10mg/
 
mL
soln for IV infusion Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin 1mg/mL soln for IV infusion after dilution 75–100mg/m² IV per cycle once every 3–4wks on Day 1
50mg/vial pwd for IV infusion after reconstitution and dilution
cyclophos
phamide
25mg, 50mg tabs 1–5mg/kg/day
500mg, 1g, 2g pwd for inj after reconsti
tution
40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan Alkeran 2mg scored tabs 0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa 15mg pwd for IV, intravesical, or intracavitary admini
stration after reconsti
tution
0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconsti
tution
Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days
2mg/mL soln for IV inj
doxorubicin (liposomal) Doxil 2mg/mL dispersion for IV infusion after dilution 50mg/m² once every 4wks; continue for ≥4 cycles as tolerated. Initial rate: 1mg/min; may increase rate to complete infusion over 1hr if no infusion reactions occur.
Antimetabolite
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after reconsti
tution
1000mg/m² on Days 1 and 8 of each 21-day cycle; give with carboplatin AUC 4 administered on Day 1 after gemcitabine
Infugem 1200mg/120mL, 1300mg/130mL, 1400mg/140mL, 1500mg/150mL, 1600mg/160mL, 1700mg/170mL, 1800mg/180mL, 1900mg/190mL, 2000mg/200mL, 2200mg/220mL soln for IV infusion
Antimicrotubule agents
paclitaxel 6mg/mL soln for IV infusion after dilution Previously untreated ovarian cancer: 175mg/m² IV over 3hrs + cisplatin; or 135mg/m² IV over 24hrs + cisplatin; repeat every 3wks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
niraparib Zejula 100mg caps 300mg once daily until disease progression or unacceptable toxicity
olaparib Lynparza 100mg, 150mg tabs 300mg twice daily.
First-line maintenance of BRCA-mutated advanced ovarian: continue until disease progression, unacceptable toxicity, or completion of 2yrs of treatment. Discontinue if complete response at 2yrs; may treat beyond 2yrs in those with evidence of disease if provider can derive further benefit from continuous treatment.
Maintenance of recurrent ovarian or germline BRCA-mutated advanced ovarian: continue until disease progression or unacceptable toxicity.
rucaparib Rubraca 200mg, 250mg, 300mg tabs 600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan Hycamtin 4mg pwd for IV infusion after reconsti
tution and dilution
1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
NOTES

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 4/2020)

This article originally appeared on MPR